Antibody Engineering
DOI: 10.1385/1-59259-666-5:519
|View full text |Cite
|
Sign up to set email alerts
|

Antibodies in Proteomics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
4
0

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 114 publications
0
4
0
Order By: Relevance
“…The extracted total RNA was used as template for 5 0 -RACE-ready cDNA synthesis (Takara Bio, Mountain View, CA). The heavy chain variable domain (VH) and the light chain variable domain (VK) of 4D9 were amplified separately by PCR using the 5 0 -RACE adaptor-specific forward primer, rat IgG, or kappa constantspecific reverse primers (Bradbury, 2010). For VK domain amplification, a peptide nucleic acid oligo (CCTGTGGAGGAGGAG-GATGCT-KK) was used to selectively amplify the functional kappa chain (Cochet et al, 1999).…”
Section: Hybridoma Antibody Sequencingmentioning
confidence: 99%
“…The extracted total RNA was used as template for 5 0 -RACE-ready cDNA synthesis (Takara Bio, Mountain View, CA). The heavy chain variable domain (VH) and the light chain variable domain (VK) of 4D9 were amplified separately by PCR using the 5 0 -RACE adaptor-specific forward primer, rat IgG, or kappa constantspecific reverse primers (Bradbury, 2010). For VK domain amplification, a peptide nucleic acid oligo (CCTGTGGAGGAGGAG-GATGCT-KK) was used to selectively amplify the functional kappa chain (Cochet et al, 1999).…”
Section: Hybridoma Antibody Sequencingmentioning
confidence: 99%
“…In the rapidly growing fields of proteomics and glycomics, in-depth analysis of protein expression, modification, and interaction on a genomic scale requires the development of specific and high-affinity reagents. Traditionally, proteinogenic polymers, especially antibodies, have served in this role; however, they suffer from a number of shortcomings, ranging from poor stability and variable production quality to limited target availability and issues with specificity profiles. Despite over 500 000 commercially available antibodies, researchers continue to express concerns over accessibility to high-quality antibodies for biomedical research. These issues have stimulated the development of alternative technologies to generate high-affinity reagents for proteins that rival the performance of traditional antibodies. …”
mentioning
confidence: 99%
“…1). In the future, however, the alternative approaches of generating recombinant antibody molecules may well supplement or replace these strategies once brought to a comparable maturation (Bradbury, 2003;Bradbury et al, 2004).…”
Section: In Vitro Antibody Generationmentioning
confidence: 99%